{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:05:41Z","timestamp":1771722341845,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10067-023-06646-0","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T14:01:25Z","timestamp":1685196085000},"page":"2287-2295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prevalence and factors associated with polypharmacy among patients with rheumatoid arthritis: a single-centre, cross-sectional study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-6356","authenticated-orcid":false,"given":"Hirofumi","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1455-6822","authenticated-orcid":false,"given":"Ryuichi Minoda","family":"Sada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-8480","authenticated-orcid":false,"given":"Hiroyuki","family":"Akebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-5710","authenticated-orcid":false,"given":"Yukio","family":"Tsugihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"6646_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17:230. https:\/\/doi.org\/10.1186\/s12877-017-0621-2","journal-title":"BMC Geriatr"},{"key":"6646_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pds.1984","volume":"19","author":"FT Bourgeois","year":"2010","unstructured":"Bourgeois FT, Shannon MW, Valim C, Mandl KD (2010) Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf 19:901\u2013910. https:\/\/doi.org\/10.1002\/pds.1984","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6646_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/0971-6580.94506","volume":"19","author":"S Rambhade","year":"2012","unstructured":"Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A (2012) A survey on polypharmacy and use of inappropriate medications. Toxicol Int 19:68\u201373. https:\/\/doi.org\/10.4103\/0971-6580.94506","journal-title":"Toxicol Int"},{"key":"6646_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB (2019) Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 58:1767\u20131776. https:\/\/doi.org\/10.1093\/rheumatology\/kez037","journal-title":"Rheumatology (Oxford)"},{"key":"6646_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/rheumatology\/kex469","volume":"57","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe S, Rutherford AI, Byng-Maddick R, Leanne Hyrich K, Benjamin Galloway J (2018) Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 57:651\u2013655. https:\/\/doi.org\/10.1093\/rheumatology\/kex469","journal-title":"Rheumatology (Oxford)"},{"key":"6646_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/mr\/roab130","volume":"32","author":"T Furuya","year":"2022","unstructured":"Furuya T (2022) Clinical observations of osteoporosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 32:839\u2013845. https:\/\/doi.org\/10.1093\/mr\/roab130","journal-title":"Mod Rheumatol"},{"key":"6646_CR7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3899\/jrheum.160818","volume":"44","author":"M Filkova","year":"2017","unstructured":"Filkova M, Carvalho J, Norton S, Scott D, Mant T, Molokhia M, Cope A, Galloway J (2017) Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis. J Rheumatol 44:1786\u20131793. https:\/\/doi.org\/10.3899\/jrheum.160818","journal-title":"J Rheumatol"},{"key":"6646_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/RHU.0000000000000463","volume":"22","author":"LM Gonz\u00e1lez-Gamboa","year":"2016","unstructured":"Gonz\u00e1lez-Gamboa LM, Barocio-Ram\u00edrez AK, Rocha-Mu\u00f1oz AD, de Santos-\u00c1vila F, Meda-Lara RM, Gonz\u00e1lez-L\u00f3pez L, G\u00e1mez-Nava JI, G\u00f3mez-Ba\u00f1uelos E, Chavarria-Avila E, Dur\u00e1n-Barrag\u00e1n S, Navarro-Hern\u00e1ndez RE, Pizano-Mart\u00ednez OE, Nu\u00f1ez-Atahualpa L, V\u00e1zquez-Del Mercado M (2016) Disease Activity Score on 28 ioints and polypharmacy are independent predictors for health-related quality of life evaluated by INCAVISA in patients with rheumatoid arthritis. J Clin Rheumatol 22:399\u2013404. https:\/\/doi.org\/10.1097\/RHU.0000000000000463","journal-title":"J Clin Rheumatol"},{"key":"6646_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/msc.112","volume":"5","author":"GJ Treharne","year":"2007","unstructured":"Treharne GJ, Douglas KM, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, Piper H, Erb N, Kitas GD (2007) Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care 5:175\u2013190. https:\/\/doi.org\/10.1002\/msc.112","journal-title":"Musculoskeletal Care"},{"key":"6646_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0897190019869158","volume":"34","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, Albuquerque CP, Santos ABV, Amorim RBC, B\u00e9rtolo MB, J\u00fanior PL, Santos IA, Giorgi RD, Sacilotto NC, Radominski SC, Borghi FM, Guimar\u00e3es MFBR, Pinto MRC, Resende GG, Bonfiglioli KR, Carri\u00e7o H, Sauma MFLC, Sauma ML, Medeiros JB, Pereira IA, Castro GRW, Brenol CV, Xavier RM, Mota LMH, Pinheiro GRC (2021) High levels of polypharmacy in rheumatoid arthritis-a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract 34:365\u2013371. https:\/\/doi.org\/10.1177\/0897190019869158","journal-title":"J Pharm Pract"},{"key":"6646_CR11","doi-asserted-by":"publisher","unstructured":"Miyake H, Minoda Sada R, Manabe A, Tsugihashi Y, Hatta K (2022) Factors and reasons for non-vaccination among patients with systemic lupus erythematosus: a single-centre, cross-sectional study. Intern Med:1067\u20131022. https:\/\/doi.org\/10.2169\/internalmedicine.1067-22","DOI":"10.2169\/internalmedicine.1067-22"},{"key":"6646_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac155","author":"H Miyake","year":"2022","unstructured":"Miyake H, Sada RM, Akebo H, Tsugihashi Y, Hatta K (2022) Polypharmacy prevalence and associated factors in patients with systemic lupus erythematosus: a single-centre, cross-sectional study. Mod Rheumatol. https:\/\/doi.org\/10.1093\/mr\/roac155","journal-title":"Mod Rheumatol"},{"key":"6646_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, Initiative STROBE (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147:573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010","journal-title":"Ann Intern Med"},{"key":"6646_CR14","doi-asserted-by":"publisher","first-page":"165910","DOI":"10.1016\/j.bbadis.2020.165910","volume":"1866","author":"H Liang","year":"2020","unstructured":"Liang H, Hu B, Chen L, Wang S, Aorigele, (2020) Recognizing novel chemicals\/drugs for anatomical therapeutic chemical classes with a heat diffusion algorithm. Biochim Biophys Acta Mol Basis Dis 1866:165910. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165910","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"6646_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66:407\u2013409. https:\/\/doi.org\/10.1136\/ard.2006.054205","journal-title":"Ann Rheum Dis"},{"key":"6646_CR16","first-page":"167","volume":"30","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167\u2013178","journal-title":"J Rheumatol"},{"key":"6646_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"6646_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijcard.2020.11.066","volume":"327","author":"K Sakane","year":"2021","unstructured":"Sakane K, Kanzaki Y, Tsuda K, Maeda D, Sohmiya K, Hoshiga M (2021) Disproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction. Int J Cardiol 327:105\u2013110. https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.066","journal-title":"Int J Cardiol"},{"key":"6646_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","volume":"23","author":"Japanese Society of Nephrology","year":"2019","unstructured":"Japanese Society of Nephrology (2019) Essential points from evidence-based clinical practice guidelines for Chronic Kidney Disease 2018. Clin Exp Nephrol 23:1\u201315. https:\/\/doi.org\/10.1007\/s10157-018-1648-1","journal-title":"Clin Exp Nephrol"},{"key":"6646_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/jgs.15569","volume":"66","author":"H Onoue","year":"2018","unstructured":"Onoue H, Koyama T, Zamami Y, Hagiya H, Tatebe Y, Mikami N, Shinomiya K, Kitamura Y, Hinotsu S, Sendo T, Ouchi Y, Kano MR (2018) Trends in polypharmacy in Japan: a nationwide retrospective study. J Am Geriatr Soc 66:2267\u20132273. https:\/\/doi.org\/10.1111\/jgs.15569","journal-title":"J Am Geriatr Soc"},{"key":"6646_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/ijpp\/riab067","volume":"29","author":"RM Arabyat","year":"2021","unstructured":"Arabyat RM, Alazzam OM, Al-Azzam SI, Nusair MB (2021) Association between Charlson Comorbidity Index and polypharmacy: a retrospective database study from Jordan. Int J Pharm Pract 29:580\u2013586. https:\/\/doi.org\/10.1093\/ijpp\/riab067","journal-title":"Int J Pharm Pract"},{"key":"6646_CR22","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/pds.5321","volume":"30","author":"J Van der Heyden","year":"2021","unstructured":"Van der Heyden J, Berete F, Renard F, Vanoverloop J, Devleesschauwer B, De Ridder K, Bruy\u00e8re O (2021) Assessing polypharmacy in the older population: comparison of a self-reported and prescription based method. Pharmacoepidemiol Drug Saf 30:1716\u20131726. https:\/\/doi.org\/10.1002\/pds.5321","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6646_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ggi.12591","volume":"16","author":"T Kojima","year":"2016","unstructured":"Kojima T, Shimada K, Terada A, Nishizawa K, Matsumoto K, Yoshimatsu Y, Akishita M (2016) Association between polypharmacy and multiple uses of medical facilities in nursing home residents. Geriatr Gerontol Int 16:770\u2013771. https:\/\/doi.org\/10.1111\/ggi.12591","journal-title":"Geriatr Gerontol Int"},{"key":"6646_CR24","doi-asserted-by":"publisher","first-page":"193168","DOI":"10.1155\/2012\/193168","volume":"2012","author":"A Vyas","year":"2012","unstructured":"Vyas A, Pan X, Sambamoorthi U (2012) Chronic condition clusters and polypharmacy among adults. Int J Family Med 2012:193168. https:\/\/doi.org\/10.1155\/2012\/193168","journal-title":"Int J Family Med"},{"key":"6646_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","volume":"22","author":"JP Turner","year":"2014","unstructured":"Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS (2014) Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer 22:1727\u20131734. https:\/\/doi.org\/10.1007\/s00520-014-2171-x","journal-title":"Support Care Cancer"},{"key":"6646_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/pop.2017.0065","volume":"21","author":"X Feng","year":"2018","unstructured":"Feng X, Tan X, Riley B, Zheng T, Bias T, Sambamoorthi U (2018) Polypharmacy and multimorbidity among Medicaid enrollees: a multistate analysis. Popul Health Manag 21:123\u2013129. https:\/\/doi.org\/10.1089\/pop.2017.0065","journal-title":"Popul Health Manag"},{"key":"6646_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11897-014-0186-8","volume":"11","author":"V Mastromarino","year":"2014","unstructured":"Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, Volpe M (2014) Polypharmacy in heart failure patients. Curr Heart Fail Rep 11:212\u2013219. https:\/\/doi.org\/10.1007\/s11897-014-0186-8","journal-title":"Curr Heart Fail Rep"},{"key":"6646_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","volume":"27","author":"J Beezer","year":"2022","unstructured":"Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P (2022) Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev 27:465\u2013492. https:\/\/doi.org\/10.1007\/s10741-021-10135-4","journal-title":"Heart Fail Rev"},{"key":"6646_CR29","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"6646_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2215\/CJN.03940321","volume":"16","author":"H Kimura","year":"2021","unstructured":"Kimura H, Tanaka K, Saito H, Iwasaki T, Oda A, Watanabe S, Kanno M, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ (2021) Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol 16:1797\u20131804. https:\/\/doi.org\/10.2215\/CJN.03940321","journal-title":"Clin J Am Soc Nephrol"},{"key":"6646_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/ggi.12789","volume":"17","author":"BB Bolmsj\u00f6","year":"2017","unstructured":"Bolmsj\u00f6 BB, M\u00f6lstad S, Gallagher M, Chalmers J, \u00d6stgren CJ, Midl\u00f6v P (2017) Risk factors and consequences of decreased kidney function in nursing home residents: a longitudinal study. Geriatr Gerontol Int 17:791\u2013797. https:\/\/doi.org\/10.1111\/ggi.12789","journal-title":"Geriatr Gerontol Int"},{"key":"6646_CR32","doi-asserted-by":"publisher","first-page":"10440","DOI":"10.1038\/s41598-019-46849-7","volume":"9","author":"H Kang","year":"2019","unstructured":"Kang H, Hong SH (2019) Risk of kidney dysfunction from polypharmacy among older patients: a nested case-control study of the South Korean senior cohort. Sci Rep 9:10440. https:\/\/doi.org\/10.1038\/s41598-019-46849-7","journal-title":"Sci Rep"},{"key":"6646_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jamda.2019.07.007","volume":"21","author":"R Ernst","year":"2020","unstructured":"Ernst R, Fischer K, de GodoiRezende Costa Molino C, Orav EJ, Theiler R, Meyer U, Fischler M, Gagesch M, Amb\u00fchl PM, Freyst\u00e4tter G, Egli A, Bischoff-Ferrari HA (2020) Polypharmacy and kidney function in community-dwelling adults age 60 years and older: a prospective observational study. J Am Med Dir Assoc 21:254-259.e1. https:\/\/doi.org\/10.1016\/j.jamda.2019.07.007","journal-title":"J Am Med Dir Assoc"},{"key":"6646_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40266-018-0563-1","volume":"35","author":"A Secora","year":"2018","unstructured":"Secora A, Alexander GC, Ballew SH, Coresh J, Grams ME (2018) Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults. Drugs Aging 35:735\u2013750. https:\/\/doi.org\/10.1007\/s40266-018-0563-1","journal-title":"Drugs Aging"},{"key":"6646_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00508-017-1253-4","volume":"129","author":"K Silay","year":"2017","unstructured":"Silay K, Yalcin A, Akinci S, Gursoy FG, Sener Dede D (2017) Charlson Comorbidity Index, inappropriate medication use and cognitive impairment: Bermuda Triangle. Wien Klin Wochenschr 129:799\u2013804. https:\/\/doi.org\/10.1007\/s00508-017-1253-4","journal-title":"Wien Klin Wochenschr"},{"key":"6646_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1370\/afm.778","volume":"5","author":"SW Mercer","year":"2007","unstructured":"Mercer SW, Watt GC (2007) The inverse care law: clinical primary care encounters in deprived and affluent areas of Scotland. Ann Fam Med 5:503\u2013510. https:\/\/doi.org\/10.1370\/afm.778","journal-title":"Ann Fam Med"},{"key":"6646_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1471-2458-12-201","volume":"12","author":"CB Agborsangaya","year":"2012","unstructured":"Agborsangaya CB, Lau D, Lahtinen M, Cooke T, Johnson JA (2012) Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey. BMC Public Health 12:201. https:\/\/doi.org\/10.1186\/1471-2458-12-201","journal-title":"BMC Public Health"},{"key":"6646_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/joim.12842","volume":"285","author":"C Muth","year":"2019","unstructured":"Muth C, Blom JW, Smith SM, Johnell K, Gonzalez-Gonzalez AI, Nguyen TS, Brueckle MS, Cesari M, Tinetti ME, Valderas JM (2019) Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus. J Intern Med 285:272\u2013288. https:\/\/doi.org\/10.1111\/joim.12842","journal-title":"J Intern Med"},{"key":"6646_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van MA, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06646-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:08:44Z","timestamp":1691579324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6646"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06646-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The Institutional Review Board of Tenri Hospital approved this study protocol (Number 1274), and all participants provided written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}